Tagged with Fujifilm

Europe Pharma and biotech companies are doubling down on innovation and, often, outsourcing just about everything else. That shift has turned contract development and manufacturing organisations (CDMOs) into critical partners, not just service providers. The sector is booming, but pressure is building fast: demand is surging, capacity is stretched, and new…

Denmark Christian Houborg, General Manager and Senior Vice President of FUJIFILM Biotechnologies Denmark, shares how the Hillerød site has evolved from a legacy facility into a cornerstone of the company’s global CDMO network. From expanding capacity to embracing cutting-edge technologies like AI and digitalisation, FUJIFILM Biotechnologies is setting new standards for…

Saudi Arabia Michio Kondo, Fujifilm’s MEA managing director, discusses the company’s remarkable growth in the Middle East and Africa since 2022, highlighting key developments such as the acquisition of Hitachi’s imaging division in 2021, which expanded their product portfolio to include MRI, CT, and ultrasound equipment. Fujifilm has also strengthened its presence…

Mexico Whenever the international investor community contemplates doing business in Mexico’s life science sector, the primary appeal usually derives from the sheer size of the marketplace and its underlying growth potential associated with trends in the country’s population demographics. Much attention is thus given over to devising strategies to win public…

Mexico Mexico has firmly established itself as a regional powerhouse in medical device manufacturing. The country is home to the second-largest medtech market in Latin America, employs around 160,000 people in the sector, and exports around USD 6.4 billion worth of medical devices annually, driven by major investments from global names…

Mexico Enrique Giraud de Haro, President & GM at Fujifilm Mexico, highlights the company’s growth alongside Fujifilm’s expansion in the region. He discusses the importance of fostering a preventive healthcare culture, especially among younger generations, and the role of innovation in Mexico’s evolving healthcare landscape.   Investing in children’s health education…

Global Originally seen as occasional service providers for the pharma industry, contract development and manufacturing organisations (CDMOs) have become vital strategic partners. Helping pharma and biotech companies advance their therapies through their outsourced services, CDMOs have demonstrated their ability to respond to the industry’s shifting priorities as well as its pre-…

Middle East & Africa  Fujifilm’s managing director for the Middle East, Michio Kondo, outlines the company’s move from products to comprehensive healthcare solutions, and how this transformation aligns with the GCC region’s view on the future of healthcare. In addition, Kondo comments on the recognition of the made-in-Japan brand, the implementation of AI in…

Global The Contract Development and Manufacturing Organisation (CDMO) industry has boomed in recent years, with Big Pharma increasingly focusing on its core business of R&D and outsourcing other elements of the supply chain, including manufacturing, to third-party CDMOs. Additionally, the global proliferation of biotechs – most of which lack the in-house…

China The latest news from Chinese pharma, including an examination of the new national reimbursement drug list (NRDL), the therapies that have and have not made it onto the list, and the significant price cuts that have been agreed. Also included are the World Health Organization (WHO)’s plea to Chinese COVID-19…

Medtech Saudi Arabia is seeing an increased demand for more innovative medical devices and a greater awareness of the myriad ways that medical technology can be used for screening illnesses such as cardiovascular disease, cancer and diabetes. Stakeholders from three multinational medtech firms commented on their strategies for growth in this…

Long Read Accounting for less than two percent of the global pharmaceutical market, the Middle East has long been somewhat overlooked by many drug makers, most of whom seemed more intent on chasing demand in the decidedly more populous Asian market space. But, with an estimated annual growth rate of 10 percent,…